Arbor Biotechnologies sets out CNS gene editing push with three ALS candidates at Meeting on the Mesa
CEO Devyn Smith presented preclinical data for gene editing programs targeting C9orf72, STMN2 and UNC13A, with a first CNS IND filing targeted for 2027.